OHIO DEPARTMENT OF MEDICAID
Pharmacy & Therapeutics Committee
Ohio Department of Medicaid, 50 West Town Street, Room C621
January 15th, 2020
10:00 A.M.

AGENDA

I. Call to Order
II. Introductions
III. Administrative Matters
   a. Conflict of Interest Statement
IV. Department of Medicaid Update
V. Approval of October 2nd, 2019 Meeting Minutes
VI. Drug Class Announcements
   a. Cystic Fibrosis
VII. Interested Party Presentations
VIII. Preferred Drug List (PDL) Proposal
   a. Katerzia™ (amlodipine suspension), Silvergate Pharmaceuticals, Calcium Channel Blockers-Dihydropyridine
   b. Nayzilam® (midazolam nasal spray), UCB, Anticonvulsants: First Generation
   d. Drizalma Sprinkle™ (duloxetine DR), Sun Pharmaceutical Industries, CNS Agents, Antidepressants: Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
   e. Adhansia XR™ (methylphenidate ER cap), Adlon Therapeutics, CNS Agents: Attention Deficit Hyperactivity Disorder Agents – Long Acting, Solid
   f. Lucemyra™ (lofexidine tab), US WorldMeds, Central Nervous System Agents: Medication Assisted Treatment Of Opioid Addiction - Chemical Dependency Agents
   g. Nourianz™ (istradefylline tab), Kyowa Kirin, CNS Agents: Parkinson’s Agents
   h. Rybelsus® (semaglutide tab), Novo Nordisk, Endocrine Agents: Diabetes –Glucagon-Like Peptide-1 Receptor Agonists
   i. Rinvoq™ (upadacitinib ER tab), AbbVie, Immunomodulator Agents for Systemic Inflammatory Disease - Janus Kinase Inhibitor
   j. ProAir® Digihaler™ (albuterol DPI), Teva Respiratory, Respiratory Agents: Beta-Adrenergic Agonists – Inhaled, Short Acting
   k. Duaklir® Pressair® (aclidinium bromide and formoterol fumarate DPI), Circassia Pharmaceuticals, Respiratory Agents: Beta-Adrenergic-Muscarinic Combinations (LABA/LAMA)
   l. Fasenra® (benralizumab SC injection), AstraZeneca, Anti-Inflammatory Interleukin Receptor Antagonist
IX. Other Business
   a. Pediatric Strengths of Harvoni™ (ledipasvir and sofosbuvir tab), Gilead Sciences, Infectious Disease Agents: Hepatitis C – Direct-Acting Antiviral
b. Pediatric Strengths of Sovaldi® (sofosbuvir tab), Gilead Sciences, Infectious Disease Agents: Hepatitis C – Direct-Acting Antiviral

c. Respiratory Category Revisions

d. Endocrine: Diabetes Cardiovascular Disease Updates

e. Future PDL Drug Class Reviews

X. 2020 Meeting Dates

a. Proposed for Quarter 2 – Wednesday, April 8th, 2020

b. Proposed for Quarter 3 – Wednesday, July 8th, 2020

c. Proposed for Quarter 4 – Wednesday, September 30th, 2020

XI. Adjournment